Results 181 to 190 of about 42,609 (234)

Influenza Antivirals: Do We Need More Evidence? [PDF]

Pediatrics
Antoon JW.
europepmc   +1 more source

Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. [PDF]

Clin Infect Dis
Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, Rhoads JP, Baughman A, Casey JD, Blair PW, Jones ID, Johnson CA, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Busse LW, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Hough CL, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Martinez A, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, Goyal A, DeLamielleure LE, DeCuir J, Surie D, Dawood FS, Tenforde MW, Uyeki TM, Garg S, Garg S, Ellington S, Self WH, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network .   +57 more
europepmc   +1 more source

Asymptomatic Human Infections With Avian Influenza A(H5N1) Virus Confirmed by Molecular and Serologic Testing: A Scoping Review.

JAMA Netw Open
Dawood FS, Garg S, Patel P, Uyeki TM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Oseltamivir

Drugs, 2013
exaly   +3 more sources

Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.

Journal of Infection and Chemotherapy, 2023
INTRODUCTION Baloxavir marboxil (BXM), a newly developed cap-dependent endonuclease inhibitor, is widely used to treat influenza virus infections in inpatients and outpatients.
C. Shiraishi, Hideo Kato, M. Hagihara, N. Asai, Takuya Iwamoto, H. Mikamo   +5 more
semanticscholar   +1 more source

Frequency and distribution of H1N1 influenza A viruses with oseltamivir‐resistant mutations worldwide before and after the 2009 pandemic

Journal of Medical Virology, 2022
H1N1 influenza has brought serious threats to people's health and a high socioeconomic burden to society. Oseltamivir, a kind of neuraminidase (NA) inhibitor, is the second‐generation specific drug that is broadly used currently.
Weixu Zhang, Hefeng Xu, S. Guan, Chengmin Wang, Guoying Dong   +4 more
semanticscholar   +1 more source

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

Journal of Biomolecular Structure and Dynamics, 2020
A novel coronavirus (SARS-CoV-2) has caused a major outbreak in humans all over the world, and it is the latest pandemic in the series of other infectious diseases.
Nisha Muralidharan, Ramasamy Sakthivel, D. Velmurugan, M. Gromiha   +3 more
semanticscholar   +1 more source

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.

The Lancet Haematology, 2021
BACKGROUND Primary immune thrombocytopenia is an autoimmune bleeding disorder. Preclinical reports suggest that the sialidase inhibitor oseltamivir induces a platelet response in the treatment of immune thrombocytopenia.
Lu Sun, Juan Wang, L. Shao, Cheng-lu Yuan, Hong-guo Zhao, Daqi Li, Zhencheng Wang, P. Han, Yafei Yu, Miao Xu, Hongyu Zhao, Jihua Qiu, Hai Zhou, Xinguang Liu, Yu Hou, J. Peng, M. Hou   +16 more
semanticscholar   +1 more source

Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019-2020 influenza season.

Journal of Infectious Diseases, 2021
BACKGROUND We aimed to detect influenza variants with reduced susceptibility to baloxavir marboxil (baloxavir) and oseltamivir and identify differences in the clinical course between children with and without these variants after anti-viral treatment ...
Masatoki Sato, E. Takashita, M. Katayose, K. Nemoto, N. Sakai, Seiichiro Fujisaki, K. Hashimoto, M. Hosoya   +7 more
semanticscholar   +1 more source

Oseltamivir

Drugs, 1999
Oseltamivir is the oral prodrug of GS4071, a selective inhibitor of influenza A and B viral neuraminidase. After absorption from the gastrointestinal tract oseltamivir is efficiently converted to GS4071, which is maintained at high and sustained concentrations in plasma. Based on studies in rats and ferrets, GS4071 appears to be effectively distributed
A, Bardsley-Elliot, S, Noble
openaire   +2 more sources